High-Dose Somatostatin Analogs for the Treatment of Neuroendocrine Neoplasms: where are we Now?

Teresa Alonso-Gordoa, Ray Manneh, Enrique Grande, Javier Molina-Cerrillo

Current treatment options in oncology 2022 Jul

filter terms:

Neuroendocrine tumors (NET) represent a complex and heterogeneous group of malignancies arising from the diffuse endocrine cells and other cells derived from the neural crest. Advanced disease is observed at diagnosis in more than one-third of patients. Somatostatin analogs (SSA) are the cornerstone in advanced well-differentiated NET treatment. Unfortunately, most patients will eventually develop resistance to SSA treatment by different mechanisms that are not fully understood. In some cases of refractory carcinoid syndrome or progressive disease, the increase of SSA dose may help to reach out a symptomatic and/or tumor growth control. The clinical evidence behind above-label SSA administration is limited and should be individualized and discussed patient by patient. Some questions regarding high-dose SSA use are unsolved, such as the optimal dose to use, the frequency of administration, or the need of deepen molecular understanding that could help to adequately select patients for this approach. © 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Citation

Teresa Alonso-Gordoa, Ray Manneh, Enrique Grande, Javier Molina-Cerrillo. High-Dose Somatostatin Analogs for the Treatment of Neuroendocrine Neoplasms: where are we Now? Current treatment options in oncology. 2022 Jul;23(7):1001-1013